[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 160,440,352
  • Shares Outstanding, K 1,241,222
  • Annual Sales, $ 29,443 M
  • Annual Income, $ 8,510 M
  • EBIT $ 10,022 M
  • EBITDA $ 12,782 M
  • 60-Month Beta 0.39
  • Price/Sales 5.39
  • Price/Cash Flow 12.20
  • Price/Book 7.01

Options Overview Details

View History
  • Implied Volatility 36.16% (+1.46%)
  • Historical Volatility 20.65%
  • IV Percentile 85%
  • IV Rank 66.40%
  • IV High 43.61% on 05/22/25
  • IV Low 21.43% on 12/10/25
  • Expected Move (DTE 2) 2.65 (2.05%)
  • Put/Call Vol Ratio 0.35
  • Today's Volume 1,549
  • Volume Avg (30-Day) 5,532
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 164,060
  • Open Int (30-Day) 154,352
  • Expected Range 126.67 to 131.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.89
  • Number of Estimates 9
  • High Estimate $1.99
  • Low Estimate $1.74
  • Prior Year $1.81
  • Growth Rate Est. (year over year) +4.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
127.64 +1.15%
on 04/27/26
142.97 -9.69%
on 04/09/26
-5.14 (-3.83%)
since 03/27/26
3-Month
127.64 +1.15%
on 04/27/26
157.29 -17.92%
on 02/11/26
-10.44 (-7.48%)
since 01/29/26
52-Week
95.29 +35.48%
on 05/08/25
157.29 -17.92%
on 02/11/26
+24.90 (+23.89%)
since 04/29/25

Most Recent Stories

More News
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

– Novel Investigational Combination Pairs Bictegravir, Guideline-Recommended INSTI with High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor, ...

GILD : 129.44 (+0.14%)
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction,...

ACLX : 115.07 (+0.03%)
GILD : 129.44 (+0.14%)
2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down

2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down

GILD : 129.44 (+0.14%)
FAST : 43.93 (-1.68%)
AJG : 211.12 (-1.08%)
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2026 financial results and guidance will be released on Thursday, May 7, 2026 after the market closes. At 4:30 p.m. Eastern Time...

GILD : 129.44 (+0.14%)
Stocks Set to Open Lower as Oil Jumps After U.S.-Iran Tensions Flare Up; Economic Data and Earnings Awaited

June S&P 500 E-Mini futures (ESM26) are down -0.42%, and June Nasdaq 100 E-Mini futures (NQM26) are down -0.43% this morning, pointing to a lower open on Wall Street as oil prices surged following a weekend...

ALK : 38.55 (-3.12%)
AAPL : 268.98 (-0.64%)
ADI : 389.14 (+1.53%)
TXN : 269.72 (+1.78%)
UNH : 369.39 (+0.71%)
ESM26 : 7,156.50 (-0.20%)
TSLA : 371.78 (-1.13%)
T : 25.97 (-0.35%)
IBM : 229.36 (-1.58%)
RTX : 172.90 (-1.58%)
LRCX : 246.22 (-1.99%)
LOOMI.S.DX : 425.800 (-0.09%)
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration...

GILD : 129.44 (+0.14%)
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access

– Additional Commitment will Expand Access to Lenacapavir to Reach Another Million People Over the Next 3 Years –

GILD : 129.44 (+0.14%)
1 Profitable Stock for Long-Term Investors and 2 Facing Challenges

1 Profitable Stock for Long-Term Investors and 2 Facing Challenges

MHK : 102.24 (-3.82%)
MRK : 110.56 (+0.48%)
GILD : 129.44 (+0.14%)
Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks

Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks

GILD : 129.44 (+0.14%)
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD)...

GILD : 129.44 (+0.14%)
TEM : 49.74 (-2.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 132.50
2nd Resistance Point 131.49
1st Resistance Point 130.37
Last Price 129.44
1st Support Level 128.24
2nd Support Level 127.23
3rd Support Level 126.11

See More

52-Week High 157.29
Fibonacci 61.8% 133.61
Last Price 129.44
Fibonacci 50% 126.29
Fibonacci 38.2% 118.98
52-Week Low 95.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.